极低剂量糖皮质激素治疗类风湿关节炎:b/tsDMARDs启用时机对激素撤停的影响
这项前瞻性队列研究纳入2015至2020年在本机构启动首个b/tsDMARDs的229例RA患者,每6个月随访3年。68%使用极低剂量GCs(<5 mg/天),32%未用。启动b/tsDMARDs时病程较短是极低剂量GCs撤停的唯一可干预预测因素(OR 1.1,95%CI 1.03-1.14,每缩短1年;P=0.001)。持续使用极低剂量GCs与持续中度疾病活动相关,并与高血压(20% vs 11%)和心肌梗死(2.3% vs 0%)相关。
要点
- 启动b/tsDMARDs时病程较短是极低剂量GCs撤停的唯一可干预预测因素(OR 1.1,95%CI 1.03-1.14,每缩短1年;P=0.001)。
- 持续使用极低剂量GCs与持续中度疾病活动显著相关。
- 极低剂量GCs使用与高血压(20% vs 11%)和心肌梗死(2.3% vs 0%)相关。
核心结论
- 相当比例接受b/tsDMARDs治疗的RA患者继续使用极低剂量GCs而未显著改善疾病控制,但似增加心血管疾病负担。
研究设计与样本
- 前瞻性队列研究,纳入2015至2020年在本机构启动首个b/tsDMARDs的所有RA患者,每6个月随访3年。
主要发现
- 共纳入229例RA患者,68%使用极低剂量GCs,32%未用GCs。
- b/tsDMARDs治疗3年后,32%从未停用、20%曾用曾停、23%永久停用极低剂量GCs,25%从未使用GCs。
- 启动b/tsDMARDs时病程较短是极低剂量GCs撤停的唯一可干预预测因素(OR 1.1,95%CI 1.03-1.14,每缩短1年;P=0.001)。
- 持续使用极低剂量GCs与持续中度疾病活动显著相关。
- 使用极低剂量GCs与高血压(20% vs 11%)和心肌梗死(2.3% vs 0%)相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We investigated the effectiveness and safety of very-low-dose (<5 mg/day) glucocorticoids (GCs) in patients with RA treated with biologic and targeted synthetic DMARDs (b/tsDMARDs). METHODS: In this prospective cohort study, we included all RA patients who started their first b/tsDMARDs at our institution between 2015 and 2020 and were monitored every 6 months for 3 years. Relationships between exposure to very-low-dose GCs and disease activity were examined through multivariable logistic regression and repeated-measures analysis of variance. The impact of very-low-dose GCs on safety was also evaluated. RESULTS: We enrolled 229 RA patients, of whom 68% were prescribed very-low-dose GCs and 32% received no GCs. After 3 years on b/tsDMARDs, 32% had never abandoned, 20% had gone on and off and 23% had permanently discontinued very-low-dose GCs, while 25% had never taken GCs. Shorter disease duration at b/tsDMARD initiation was the single modifiable predictor of very-low-dose GC cessation [odds ratio 1.1 (95% CI 1.03, 1.14) for any 1-year decrease; P = 0.001]. A significant association existed between ongoing utilization of very-low-dose GCs and persistent moderate disease activity. Use of very-low-dose GCs was associated with hypertension (20% vs 11%) and myocardial infarction (2.3% vs 0%). CONCLUSION: A substantial proportion of RA patients treated with b/tsDMARDs continue to receive very-low-dose GCs without significantly improving disease control. However, this appears to increase cardiovascular morbidity.
引用
- Giollo A, Salvato M, Frizzera F, et al. Very-low-dose glucocorticoid therapy in rheumatoid arthritis: impact of b/tsDMARDs initiation timing on glucocorticoid withdrawal. Rheumatology (Oxford). 2025. PMID: 38310364. doi:10.1093/rheumatology/keae077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。